BRAINTREE, Mass., Jan. 30, 2013 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) today reported third quarter 2013 net revenue of $247.4 million, up 29%, GAAP net income of $9.9 million, down 46%, and diluted earnings per share of $0.19, down 47%. Adjusted net income, exclusive of restructuring and other costs detailed below, was $26.4 million, up 20%, and adjusted earnings per share were $0.50, up 16%.1
Organic net revenue, exclusive of the recently acquired whole blood business, was $192.5 million, up 1% in the third quarter and $558.5 million, up 3% year-to-date. Organic growth rates were not materially impacted by currency on a quarterly or year-to-date basis. Excluding currency impacts, net revenue was up 31% in the third quarter and 19% year-to-date.
Brian Concannon, Haemonetics' President and CEO, commented: "The highlight of our third quarter was the earnings power that became more visible in our business. Our profitability was driven by the ongoing contribution from our recent whole blood acquisition and continued solid organic revenue growth in our Hospital business on the strength of strong demand for the Cell Saver® Elite® and TEG® disposables. Our Hospital customers continue to embrace our Blood Management Solutions, recognizing the inherent value proposition offered."STRATEGIC AND PRODUCT GROWTH HIGHLIGHTSHaemonetics continues to make progress expanding its business, reporting the following third quarter highlights:
|SOURCE Haemonetics Corporation|
Copyright©2012 PR Newswire.
All rights reserved